Digestive Diseases and Sciences

, Volume 40, Supplement 2, pp 63S–80S

Safety of acid-suppressing drugs

  • Richard A. Smallwood
  • Roger G. Berlin
  • Neal Castagnoli
  • Henk P. M. Festen
  • Christopher J. Hawkey
  • S. K. Lam
  • Michael J. S. Langman
  • Per Lundborg
  • Andrew Parkinson


There is an extensive literature on the adverse effects of drugs that inhibit gastric acid secretion. This study presents a critical examination of interactions between antisecretory drugs and other compounds, the frequency of serious adverse effects relating to various body systems, the safety of antisecretory drugs in pregnancy, and longer-term safety data from postmarketing surveillance studies. While interactions with some other drugs, alcohol, and certain carcinogens are of potential concern, in practice clinically significant reactions appear to be rare if they occur at all. A small number of major side-effects have been documented, but they occur rarely, and postmarketing surveillance has not detected other longer-term sequelae. Safety of these drugs in pregnancy is not established, as data are so few. It is concluded that antisecretory agents, by comparison with most other classes of drugs, are remarkably well tolerated.

Key Words

antisecretory drugs drug-drug interactions drugs in pregnancy drug toxicity gastric ADH P-450 induction P-450 inhibition surveillance 


  1. 1.
    Lewis JH: Hepatic effects of drugs used in the treatment of peptic ulcer disease. Am J Gastroenterol 82:987–1003, 1987Google Scholar
  2. 2.
    Gugler R, Allgayer H: Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet 18:210–219, 1990Google Scholar
  3. 3.
    Black M: Hepatotoxic and hepatoprotective potential of histamine (H2)-receptor antagonists. Am J Med 83:68–75, 1987Google Scholar
  4. 4.
    Krishna DR, Klotz U Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential. Clin Pharmacokinet 15:205–215, 1988Google Scholar
  5. 5.
    Smith SR, Kendall MJ: Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions. Clin Pharmacokinet 15:44–56, 1988Google Scholar
  6. 6.
    Mitchard M, Harris A, Mullinger BM: Ranitidine interactions: A literature review. Pharmacol Ther 32:293–325, 1987Google Scholar
  7. 7.
    Klotz U, Kroemer HK: The drug interaction potential of ranitidine: An update. Pharmacol Ther 50:233–244, 1991Google Scholar
  8. 8.
    Somogyi A, Muirhead M: Pharmacokinetic interaction of cimetidine. Clin Pharmacokinet 12:321–366, 1987Google Scholar
  9. 9.
    Greene W: Drug interactions involving cimetidine-mechanisms, documentation, implications. Q Rev Drug Metab Drug Interact 5:25–51, 1984Google Scholar
  10. 10.
    Howell JR, Donn KH: Histamine H2-antagonists drug interactions in perspective: Mechanistic concepts and clinical implications. Am J Med 77:57–84, 1984Google Scholar
  11. 11.
    Baciewicz AM, Baciewicz FA: Effect of cimetidine and ranitidine on cardiovascular drugs. Am Heart J 118:144–154, 1989Google Scholar
  12. 12.
    Sax MJ: Clinically important adverse effects and drug interactions with H2-receptor antagonists: An update. Pharmacotherapy 7:110S-115S, 1987Google Scholar
  13. 13.
    Reilly CS, Biollaz J, Koshakji RP, Wood AJ: Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism. Clin Pharmacol Ther 40:37–41, 1986Google Scholar
  14. 14.
    Klotz U, Reimann J: Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. Eur J Clin Pharmacol 18:517–520, 1980Google Scholar
  15. 15.
    Sachs G, Kowalsky SF: Acetaminophen interaction with cimetidine and ranitidine: A critical analysis of the literature. Adv Ther 5:257–272, 1988Google Scholar
  16. 16.
    Heagerty AM, Donovan MA, Castleden CM, Pohl JF, Patel L, Hedges A: Influence of cimetidine on pharmacokinetics of propranolol. BMJ 282:1917–1919, 1981Google Scholar
  17. 17.
    Kirch W, Janisch HD, Heidemann H, Ramsch K, Ohnhaus EE: Effect of cimetidine and ranitidine on the pharmacokinetics and the antihypertensive action of nifedipine. Dtsch Med Wochenschr 108:1757–1761, 1983Google Scholar
  18. 18.
    Winship LC, McKenney JM, Wright JT, Wood JH, Goodman RP: The effect of ranitidine and cimetidine on single dose diltiazem pharmacokinetics. Pharmacotherapy 5:16–19, 1985Google Scholar
  19. 19.
    Smith MJ, Benyunes MC, Björnsson TD, Shand DG, Pritchett ELC: Influence of cimetidine on verapamil kinetics and dynamics. Clin Pharmacol Ther 36:551–554, 1984Google Scholar
  20. 20.
    Feeley J, Wilkinson GR, McAllister CB, Wood AJB: Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med 96:593–594, 1982Google Scholar
  21. 21.
    Somogyi A, Bochner F: Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol 18:175–181, 1984Google Scholar
  22. 22.
    Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L: Slow omeprazole metabolisers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12:415–416, 1990Google Scholar
  23. 23.
    Toon S, Hopkins KJ, Garstang FM, Rowland M: Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. J Clin Pharmacol 32:165–172, 1987Google Scholar
  24. 24.
    Gaska JA, Tietze KJ, Rocci ML, Vlasses PH: Theophylline pharmacokinetics—effect of continuous versus intermittent cimetidine IV infusion. J Clin Pharmacol. 31:668–672, 1991Google Scholar
  25. 25.
    Chanery RJ, Ayrton A, Oldham HC, Norman BJ, Standring P: The interaction of omeprazole with rat liver cytochrome P-450-mediated monooxygenase reactionsin vitro andin vivo. Biochem Pharmacol 37:1407–1414, 1986Google Scholar
  26. 26.
    Henry DA, Somerville KW, Kitchingman G, Langman MJS: Omeprazole: Effects on oxidative drug metabolism. Br J Clin Pharmacol 18:195–200, 1984Google Scholar
  27. 27.
    Oosterhuis B, Jonkman JHG: Omeprazole: Pharmacology, pharmacokinetics and interactions. Digestion 44(suppl 1): 9–17, 1989Google Scholar
  28. 28.
    Gugler R, Jensen JC: Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoinin vivo and 7-ethoxycoumarinin vitro. Gastroenterology 89:1235–1241, 1985Google Scholar
  29. 29.
    Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P: Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Pharmacol 39:51–54, 1990Google Scholar
  30. 30.
    Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P: Effects of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 47:79–85, 1990Google Scholar
  31. 31.
    Sutfin T, Balmer K, Boström H, Eriksson S, Höglund P, Paulsen O: Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 11:176–184, 1989Google Scholar
  32. 32.
    Andersson T, Lagerström P, Unge P: A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 12:329–333, 1990Google Scholar
  33. 33.
    Prichard PJ, Walt RP, Kitchingman GK, Somerville KW, Langman MJS, Williams J, Richens A: Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 24:543–545, 1987Google Scholar
  34. 34.
    Gugler R, Jensen JC: Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolismin vivo. Pharmacol Ther 33:133–137, 1987Google Scholar
  35. 35.
    Geneve J, Bocquentin M, Taburet AM, Simoneau G, Caulin C, Singlas E: Effect of omeprazole on theophylline metabolism in healthy subjects. Gastroenterology 100:A69, 1991Google Scholar
  36. 36.
    Andersson T, Bergstrand R, Cederberg C, Eriksson S, Lagerström P, Skånberg I: Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 101:943–947, 1991Google Scholar
  37. 37.
    Andersson T, Lundborg P, Regårdh CG: Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. Eur J Clin Pharmacol 40:61–65, 1991Google Scholar
  38. 38.
    Henry D, Brent P, Whyte I, Mihaly G, Devenish-Meares S: Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 33:369–373, 1987Google Scholar
  39. 39.
    Bannister J, Noble DW, Lamont M, Scott DB: Lack of effect of omeprazole on the disposition of lignocaine and its active metabolite in healthy subjects. Anaethesia 49:497–500, 1994Google Scholar
  40. 40.
    Ching MS, Elliott SL Stead CK, Murdoch RT, Devenish-Meares SE, Morgan DJ, Smallwood RA: Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. Aliment Pharmacol Ther 5:523–531, 1991Google Scholar
  41. 41.
    Blohmé I, Andersson T, Idström JP: No interaction between omeprazole and cyclosporine. Br J Clin Pharmacol 35:155–160, 1993Google Scholar
  42. 42.
    Andersson T: Drug interaction studies with omeprazole—a review. Clin Pharmacokinet 21:195–212, 1991Google Scholar
  43. 43.
    Cohen AF, Kroon R, Schoemaker HX, Hoogkamer JFW, Van Vliet-Verbeek A: Influence of gastric acidity on the bioavailability of digoxin. Ann Intern Med 115:540–545, 1991Google Scholar
  44. 44.
    Sohn DR, Kobayashi K, Chiba K, Lee K-H, Shin S-G, Ishizaki T: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers ofS-mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther 262:1195–1202, 1992Google Scholar
  45. 45.
    Jensen JC, Gugler R: Cimetidine interaction with liver microsomesin vitro andin vivo. Involvement of an activated complex with cytochrome P-450. Biochem Pharmacol 34:2141–2146, 1985Google Scholar
  46. 46.
    Testa B, Jenner P: Inhibitors of cytochrome P-450s and their mechanism of action. Drug Metab Rev 12:1–117, 1981Google Scholar
  47. 47.
    Murray M, Wilkinson CF: Interactions of nitrogen heterocycles with cytochrome P-450 and monooxygenase activity. Chem Biol Interact 50:267–275, 1984Google Scholar
  48. 48.
    Ortiz de Montellano PR, Reich NO: Inhibition of cytochrome P-450 enzymes.In Cytochrome P-450: Structure, Mechanism and Biochemistry. de Montellano O (ed.) New York, Plenum Press, pp 274–275, 1986Google Scholar
  49. 49.
    Rogerson TD, Wilkinson CF, Hetarski K: Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes. Biochem Pharmacol 26:1039–1042, 1977Google Scholar
  50. 50.
    Rodrigues AD, Lewis DFV, Ioannides C, Parke DV: Spectral and kinetic studies of the interaction of imidazole antifungal agents with microsomal cytochromes P-450. Xenobiotica 17:1315–1327, 1987Google Scholar
  51. 51.
    Morita K, Ono T, Shimakawa H: Inhibition of testosterone biosynthesis in testicular microsomes by various imidazole drugs. Comparative study with ketoconazole. J Pharmacobiodyn 13:336–343, 1990Google Scholar
  52. 52.
    Ritter JK, Franklin MR: High magnitude hepatic cytochrome P-450 induction by anN-substituted imidazole antimycotic, clotrimazole. Biochem Pharmacol 36:2783–2787, 1987Google Scholar
  53. 53.
    Molowa SA, Thomas DT, Levin PE, Guzelian W, Guzelian PS: Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. Mol Pharmacol 35:279–285, 1989Google Scholar
  54. 54.
    Skånberg I, Boström H, Löfberg I, Suffin T: Effect of omeprazole on the metabolism of other drugs—in vivo and in vitro data. IInd international ISSX Meeting, Kobe, Japan, May 16–20, 1988 (abstract)Google Scholar
  55. 55.
    Schenkman JB, Sligar SG, Cinti DL: Substrate interactions with cytochrome P-450.In Hepatic Cytochrome P-450 Monooxygenase System. Schenkman JB, Kupfer D (eds). International Encyclopedia of Pharmacology and Therapeutics. New York, Pergamon Press, pp 587–615, 1982Google Scholar
  56. 56.
    Ioannoni B, Mason SR, Reilly PE, Winzor DJ: Evidence of induction of hepatic microsomal cytochrome P-450 by cimetidine: Binding and kinetic studies. Arch Biochem Biophys 247:372–383, 1986Google Scholar
  57. 57.
    Diaz D, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel H, Maurel, P: Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 99:737–747, 1990Google Scholar
  58. 58.
    Distelrath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson R, Guengerich FP: Purification and characterization of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetinO-deethylase, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057–9067, 1985Google Scholar
  59. 59.
    Guengerich FP, Dannan GA, Wright ST, Martin MV, Kaminsky LS: Purification and characterization of liver microsomal cytochromes P450: Electrophoresis, spectral, catalytic and immunochemical properties and inducibility of eight enzymes isolated from rats treated with phenobarbital or β-nephthoflavone. Biochemistry 21:19–30, 1982Google Scholar
  60. 60.
    McDonnell WM, Scheiman JM, Traber PG: Induction of cytochrome P4501A genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology 103:1509–1516, 1992Google Scholar
  61. 61.
    Robson RA, Miners JO, Matthews AP, Stupans I, Meller D, McManus ME, Birkett DJ: Characterisation of theophylline metabolism by human liver microsomes. Biochem Pharmacol 37:1651–1659, 1988Google Scholar
  62. 62.
    Seasardic D, Boobis AR, Murray BP, Murray S, Segura J, DeLa Torre R, Davies DS: Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651–663, 1990Google Scholar
  63. 63.
    Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF Human cytochrome P450PA (P450 1A2), the phenacetinO-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine andN-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696–7700, 1989Google Scholar
  64. 64.
    Rost KL, Brösicke H, Brokmöller J, Scheffler M, Helge H, Roots I: Increase of cytochrome P4501A2 activity by omeprazole: Evidence by the13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 52:170–180, 1992Google Scholar
  65. 65.
    Parkinson A, Hurwitz A: Omeprazole and the induction of human cytochrome P-450. A response to concerns about potential adverse effects. Gastroenterology 100:1157–1164, 1991Google Scholar
  66. 66.
    Seitz HK, Veith S, Czygan P, Bosche J, Simon B, Gugler R, Kommerell B:In vivo interactions between H2-receptor antagonists and ethanol metabolism in man and in rats. Hepatology 4:1231–1234, 1984Google Scholar
  67. 67.
    Feely J, Wood AJ: Effects of cimetidine on the elimination and actions of ethanol. JAMA 247:2819–2821, 1982Google Scholar
  68. 68.
    DiPadova C, Roine R, Frezza M, Gentry RT, Baraona E, Leiber CS: Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists. JAMA 267:83–86, 1992Google Scholar
  69. 69.
    Caballeria J, Baraona E, Rodamilans M, Lieber CS: Effects of cimetidine on gastric alcohol dehydrogenase activity and blood ethanol levels. Gastroenterology 96:388–392, 1989Google Scholar
  70. 70.
    Frezza M, Di-Padova C, Pozzato G, Terpin M, Barona E, Lieber CS: High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 322:95–99, 1990Google Scholar
  71. 71.
    Tanaka E, Nakamura K: Effects of H2-receptor antagonists on ethanol metabolism in Japanese volunteers. Br J Clin Pharmacol 26:96–99, 1988Google Scholar
  72. 72.
    Johnson KI, Fenzl E, Hein B: The effect of cimetidine on the metabolism and effects of alcohol. Arzneimittelforschung 34:734–736, 1984Google Scholar
  73. 73.
    Northop I, Kneip M, Oehmichen M, Staak M, Iffland R, Kaferstein H: The effect of the administration of H2-receptor blockers on alcohol kinetics and psychophysical fitness. Beitr Gesch Med 44:1–4, 1986Google Scholar
  74. 74.
    Dobrilla G, de Pretis G, Piazzi L, Chilovi F, Comberlato M, Valentini M, Pastorino A, Vallaperta P: Is ethanol metabolism affected by oral administration of cimetidine and ranitidine at therapeutic doses? Hepatogastroenterology 31:35–37, 1984Google Scholar
  75. 75.
    Webster LK, Jones DB, Smallwood RA: Influence of cimetidine and ranitidine on ethanol pharmacokinetics. Aust NZ J Med 15:359–360, 1985Google Scholar
  76. 76.
    Fraser AG, Prewett EJ, Hudson M, Sawyerr AM, Rosalki SB, Pounder RE: The effect of ranitidine, cimetidine or famotidine on low-dose post-prandial alcohol absorption. Aliment Pharmacol Ther 5:263–272, 1991Google Scholar
  77. 77.
    Palmer RH: Cimetidine and alcohol consumption. Gastroenterology 97:1066–1067, 1989Google Scholar
  78. 78.
    Caballeria J, Baraona E, Rodamilans M, Lieber CS: Reply to “Cimetidine and alcohol consumption.” Gastroenterology 97:1066–1067, 1989Google Scholar
  79. 79.
    Palmer RH, Frank WO, Nambi P, Wetherington JO, Fox MJ: Effects of various concomitant medications on gastric alcohol dehydrogenase and the first-pass metabolism of ethanol. Am J Gastroenterol 86:1749–1755, 1991Google Scholar
  80. 80.
    Raufman JP, Notar-Francesco V, Raffaniello RD, Straus EW: Histamine-2 receptor antagonists do not alter serum ethanol levels in fed, nonalcoholic men. Ann Intern Med 118:488–494, 1993Google Scholar
  81. 81.
    Jonsson KA, Jones AW, Boström H, Andersson T: Lack of effect of omeprazole, cimetidine and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. Eur J Clin Pharmacol 42:209–212, 1992Google Scholar
  82. 82.
    Fraser AG, Hudson M, Sawyerr AM, Smith MS, Rosalki SB, Pounder RE: Ranitidine, cimetidine, famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken after an evening meal. Aliment Pharmacol Ther 6:693–700, 1992Google Scholar
  83. 83.
    Roine R, Hernandez-Munoz R, Baraona E, Greenstein R, Leiber CS: Effect of omeprazole on gastric first-pass metabolism of ethanol. Dig Dis Sci 37:891–896, 1992Google Scholar
  84. 84.
    Fraser AG, Hudson M, Sawyerr AM, Smith MS, Sercombe J, Rosalki SB, Pounder RE: Ranitidine has no effect on postbreakfast ethanol absorption. Am J Gastroenterol 88:217–221, 1993Google Scholar
  85. 85.
    Hough LB, Green JP: Histamine receptors.In Cellular Receptors for Hormones and Neurotransmitters. Schulster D, Levitzki (eds). New York, John Wiley & Sons, pp 287–290, 1980Google Scholar
  86. 86.
    Haas HL, Konnerth A: Histamine and noradrenaline decrease calcium-activated potassium conductase in hippocampal pyramidal cells. Nature 302:432–434, 1983Google Scholar
  87. 87.
    Kagevi I, Wahlby L: CSF concentrations of ranitidine. Lancet 1:164–165, 1985Google Scholar
  88. 88.
    Kagevi I, Thorhallson E, Wahlby L: Cerebrospinal fluid concentration of famotidine. Scand J Gastroenterol 22:27, 1987Google Scholar
  89. 89.
    Jonsson KA, Eriksson SE, Kagevi I, Norlander B, Bodemar G, Walan A: No detectable concentrations of oxmetidine but measurable concentrations of cimetidine in cerebrospinalfluid (CSF) during multiple dose treatment. Br J Clin Pharmacol 17:781–782, 1984Google Scholar
  90. 90.
    Schentag JJ, Cerra FB, Calleri G, DeGlopper E, Rose JQ, Bernhard H: Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet 1:177–181, 1979Google Scholar
  91. 91.
    Kimelblatt BJ, Cerra FB, Calleri G, Berg MJ, McMillen MA, Schentag JJ: Dose and serum concentration relationship in cimetidine-associated mental confusion. Gastroenterology 78:791–795, 1980Google Scholar
  92. 92.
    Berg MJ, Schentag JJ: Cimetidine distribution in human serum, tissue and cerebrospinal fluid. Clin Pharmacol Ther 25:214, 1979Google Scholar
  93. 93.
    Lakoski JM, Aghajanian GK: Effects of histamine H1- and H2-receptor antagonists on the activity of serotonin-containing neurons in the dorsal raphe. J Pharmacol Exp Ther 227:517–523, 1983Google Scholar
  94. 94.
    Sibilia V, Netti C, Guidobono F, Pagani F, Pecile A: Cimetidine-induced prolactin release: Possible involvement of GABA-ergic system. Neuroendocrinology 40:189–192, 1985Google Scholar
  95. 95.
    Penston J, Wormsley KG: Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol 1:192–216, 1986Google Scholar
  96. 96.
    Bories P, Michel H, Duclos B, Beraud JJ, Mirouze J: Use of ranitidine, without mental confusion, in patients with renal failure. Lancet 2:755, 1980Google Scholar
  97. 97.
    Hubain PP, Sobolski J, Mendlewicz J: Cimetidine-induced mania. Neuropsychobiology 8:223–224, 1982Google Scholar
  98. 98.
    Crowder MK, Pate JK: A case-report of cimetidine-induced depressive syndrome. Am J Psychiatry 137:1451, 1980Google Scholar
  99. 99.
    Edmonds ME, Ashford RFU, Brenner MK, Saunders A: Cimetidine: Does neurotoxicity occur? Report of 3 cases. J R Soc Med 72:172–175, 1979Google Scholar
  100. 100.
    Titus JP: Cimetidine-induced mania in depressed patients. J Clin Psychiatry 44:267–268, 1983Google Scholar
  101. 101.
    Epstein CM: Ranitidine and confusion. Lancet 1:1071, 1984Google Scholar
  102. 102.
    Price W, Coli L, Brandstetter RD, Gotz VP: Ranitidine-associated hallucinations. Eur J Clin Pharmacol 29:375–376, 1985Google Scholar
  103. 103.
    Reid SR, Bayliff CD: The comparative efficiency of cimetidine and ranitidine in controlling gastric pH in critically ill patients. Can Anaesth Soc J 33:287–293, 1986Google Scholar
  104. 104.
    Barth HO, Berg P, Brunner G, Dammann HG, Friedl W, Franken FH, Greiner L, Groitl J, Mockel W, Muller P: Ranitidine and cimetidine in stress-ulcer prophylaxis: a comparative multicenter study. Lang Archir Chir 362:131–138, 1984Google Scholar
  105. 105.
    Wildeman RA: Focus on misoprostol: Review of worldwide safety data. Clin Invest Med 10:243–245, 1987Google Scholar
  106. 106.
    Bianchi-Porro G, Parente F: Side effects of anti-ulcer prostaglandins: An overview of the worldwide clinical experience. Scand J Gastroenterol 164(suppl):224–231, 1989Google Scholar
  107. 107.
    Jacquemier JM, Lassoued S, Laroche M, Mazieres B: Neurosensory adverse effects after phenylbutazone and misoprostol combined treatment. Lancet 2:1283, 1989Google Scholar
  108. 108.
    Nelis GF: Safety profile of omeprazole. Adverse events with short-term treatment. Digestion 44(suppl 1):68–76, 1989Google Scholar
  109. 109.
    Sölvell L: The clinical safety of omeprazole. Scand J Gastroenterol 166(suppl):106–113, 1989Google Scholar
  110. 110.
    Ruffenach SJ: Acute interstitial nephritis due to omeprazole. Am J Med 93:472–473, 1992Google Scholar
  111. 111.
    Christensen CK, Morgensen CE, Sörensen FA: Renal function and cimetidine. Scand J Gastroenterol 16:129–134, 1981Google Scholar
  112. 112.
    Yeung CK, Wong KL, Ng MT, Lai CL: Effects of cimetidine, ranitidine and antacid on renal function. Clin Ther 6:620–624, 1984Google Scholar
  113. 113.
    Kaye WA, Passero MA, Solomon RJ, Johnson LA: Cimetidine-induced interstitial nephritis with response to prednisolone therapy. Arch Intern Med 143:811–812, 1983Google Scholar
  114. 114.
    Pitone JM, Santoro JJ, Biondi RJ, Chiesa JC, Pecora AA: Cimetidine-induced acute interstitial nephritis. Am J Gastroenterol 77:169–171, 1982Google Scholar
  115. 115.
    Watson AJS, Dalbow MH, Stachura I, Fragola JS, Rubin MF, Watson RM, Bourke E: Immunologic studies in cimetidine-induced nephropathy and polymyositis. N Engl J Med 308:142–145, 1983Google Scholar
  116. 116.
    Rowley-Jones D, Flind AC: Cimetidine-induced renal failure. BMJ 285:1422–1423, 1982Google Scholar
  117. 117.
    Gill M, Sanyal SN, Sareen ML: Effect of histamine H2-receptor antagonist ranitidine on renal brush border and basolateral membranes. Res Exp Med 190:345–356, 1990Google Scholar
  118. 118.
    Wingo CS: Active proton secretion and potassium absorption in the rabbit outer medullary collecting duct: Functional evidence for H-K-ATPase. J Clin Invest 84:361–365, 1989Google Scholar
  119. 119.
    Garg LC, Narang N: Ouabain-insensitive K-adenosine triphosphatase in distal nephron segments of the rabbit. J Clin Invest 81:1204–1208, 1988Google Scholar
  120. 120.
    Doucet A, Marsy S: Characterization of K-ATPase activity in distal nephron stimulation by potassium depletion. Am J Physiol 253:F418-F423, 1987Google Scholar
  121. 121.
    Wingo CS, Madsen KM, Smolka A, Tisher CC: H-K-ATPase immunoreactivity in cortical and outer medullary collecting duct. Kidney Int 38:985–990, 1990Google Scholar
  122. 122.
    Howden DW, Reid JL: Omeprazole, a gastric proton pump inhibitor: Lack of effect on renal handling of electrolytes and urinary acidification. Eur J Clin Pharmacol 26:639–640, 1984Google Scholar
  123. 123.
    Descotes J: Drug-Induced DisordersIn Dukes, MNG (ed). Amsterdam, Elsevier, 1990Google Scholar
  124. 124.
    Kumar A: Cimetidine an immunomodular. DICP 24(3):289–295, 1990Google Scholar
  125. 125.
    Jorizzo JL, Sams WM Jr, Jegasothy BV, Olansky AJ: Cime-tidine as an immunomodulator: Chronic mucocutaneous candidiasis as a model. Ann Intern Med 92:192–195, 1980Google Scholar
  126. 126.
    White WB, Ballow M: Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia. N Engl J Med 312:198–202, 1984Google Scholar
  127. 127.
    Ahonen J, Paimela H, Kauste H, Häyry P, Eklund B, Pettersson E: Ranitidine and cimetidine in renal transplantation: A clinical trial. Int J Tissue React 5:373–378, 1983Google Scholar
  128. 128.
    Jacob ET, Papa M: Cimetidine and renal allograft rejection. Isr J Med Sci 19:161–164, 1983Google Scholar
  129. 129.
    Hawkins RA, Eckhoff PJ Jr, McCarter DK, Harmon CE: Cimetidine and polymyositis. N Engl J Med 309:187–188, 1983Google Scholar
  130. 130.
    Brockmeyer NH, Kreuzfelder E, Mertins L, Chalabi N, Kirch W, Scheiermann N, Goos M, Ohnhaus EE: Immunomodulatory properties of cimetidine in ARC patients. Clin Immunol Immunopathol 48:50–60, 1988Google Scholar
  131. 131.
    Descotes J, Tedone R, Eureux JCI: Effects of cimetidine and ranitidine on delayed-type hypersensitivity. Immunopharmacology 6:31–35, 1983Google Scholar
  132. 132.
    Tomioka K, Yamada T, Tachikawa S: Effects of famotidine (YM-11170), an H2-receptor antagonist, onin vivo immediate and delayed type hypersensitivity reactions and antibody formation. Drugs Exp Clin Res 9:881–889, 1983Google Scholar
  133. 133.
    Byron JW: Mechanism for histamine-H2-receptor induced cell cycle changes in the bone marrow stem cell. Agents Actions 7:209–213, 1979Google Scholar
  134. 134.
    Pixley JS, MacKintosch FR, Sahr EA, et al: Mechanism of ranitidine associated anemia. Am J Med Sci 297:369–371, 1989Google Scholar
  135. 135.
    Aymard FP, Aymard B, Netter P, Bannworth B, Trochot P, Streiff, F: Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol 3:430–448, 1988Google Scholar
  136. 136.
    Brenner LO: Agranulocytosis and ranitidine. Ann Intern Med 104:896–897, 1986, (letter)Google Scholar
  137. 137.
    Chang HU, Morrison SL: Bone marrow suppression associated with cimetidine. An Intern Med 91:580, 1979Google Scholar
  138. 138.
    McGuigan JE: Side effects of histamine2-receptor antagonists. Clin Gastroenterol 12:819–838, 1983Google Scholar
  139. 139.
    Rowley-Jones D, Flind AC: Continuing evaluation of the safety of medicine.In Cimetidine in the 80s. Baron JH (ed). Bath, The Pitman Press, 1982, p 261Google Scholar
  140. 140.
    Posnett DN, Stein RS, Graber SE, Krantz SB: Cimetidineinduced neutropenia. A possible dose related phenomenon. Arch Intern Med 139:584–586, 1979Google Scholar
  141. 141.
    Agura ED, Vila E, Petersen FB, Shields AF, Thomas ED: The use of ranitidine in bone marrow transplantation. A review of 223 cases. Transplantation 46:53–56, 1988Google Scholar
  142. 142.
    Amos RJ, Kirk B, Amess JA, Jones AL, Hinds CJ: Bone marrow hypoplasia during intensive care: Bone marrow culture studies implicating ranitidine in the suppression of haemopoiesis. Hum Toxicol 6:503–506, 1987Google Scholar
  143. 143.
    Idvall J: Cimetidine-associated thrombocytopenia. Lancet 2:159, 1979Google Scholar
  144. 144.
    Isaacs JS: Cimetidine and thrombocytopenia. BMJ 280:294, 1980Google Scholar
  145. 145.
    Van Thiel DH, Gavaler JS, Smith WI Jr, Paul G: Hypothalamic-pituitary-gonadal dysfunction in men using cimetidine. N Engl J Med 300:1012–1015, 1979Google Scholar
  146. 146.
    Wang C, Lai CL, Lam KC, Yeung KK: Effect of cimetidine on gonadal function in man. Br J Clin Pharmacol 13:791–794, 1982Google Scholar
  147. 147.
    Bohnet HG, Riley AJ: An investigation of the effect of oral ranitidine treatment on hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal function in male and female volunteers.In The Clinical Use of Ranitidine. Misiewicz JJ, Wormsley K (eds). Oxford, Medicine Publishing Foundation Series 5, 1982, pp 69–76.Google Scholar
  148. 148.
    Van Thiel DH, Gavaler JS, Heyl A, Susen B: An evaluation of the anti-androgen effects associated with H2-antagonist therapy. Scand J Gastroenterol 136(suppl):24–28, 1987Google Scholar
  149. 149.
    Bianchi-Porro G, Ragni G, Ruspa M, Petrillo M, Barattini G: Long-term treatment with cimetidine does not essentially affect the hypothalamic-pituitary-gonadal axis in man. Hepatogastroenterology 32:77–80, 1985Google Scholar
  150. 150.
    Wang C, Wong KL, Lam KD, Lai CL: Ranitidine does not affect gonadal function in man. Br J Clin Pharmacol 16:430–432, 1983Google Scholar
  151. 151.
    Funder JW, Mercer JE: Cimetidine, a histamine H2-receptor antagonist, occupies androgen receptors. J Clin Endocrinol Metab 48:189–191, 1979Google Scholar
  152. 152.
    Scobie IN, Saunders J, Barnes GD, Hoad J, Wheeler MJ, Lowry C, Sonksen PH, Amphlett G, Riley AJ: A comparative study of the effects of ranitidine and cimetidine on carbohydrate tolerance, growth hormone secretion and the hypothalamic-pituitary-gonadal axis in man. Curr Med Res Opin 10:285–290, 1986Google Scholar
  153. 153.
    Bohnet HG, Griewe M, Hander JP, Aragona C, Schneider HP: Effects of cimetidine on prolactin, LH and sex steroid secretion in male and female volunteers. Acta Endocrinol 88:428–434, 1978Google Scholar
  154. 154.
    Carlson HE, Ippoliti AF, Swerdloff RS: Endocrine effects of acute and chronic cimetidine administration. Dig Dis Sci 26:428–432, 1981Google Scholar
  155. 155.
    Valk TW, England BG, Marshall JC: Effects of cimetidine on pituitary function: Alterations in hormone secretion profiles. Clin Endocrinol 15:139–149, 1981Google Scholar
  156. 156.
    Colle M, Rudeas E, Cazenave J, Auzeric J, Basilisco G, Camboni G, Manara L: Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine. Eur J Clin Pharmacol 35:529–534 1988Google Scholar
  157. 157.
    Lardinois CK, Mazzaferri EL: Cimetidine blocks testosterone synthesis. Arch Intern Med 145:920–922, 1985Google Scholar
  158. 158.
    Knigge U, Dejgaard A, Wollesen F, Ingersley O, Bennett P, Christiansen PM: The acute and long term effect of the H2-receptor antagonists cimetidine and ranitidine on the pituitary-gonadal axis in man. Clin Endocrinol 18:307–313, 1983Google Scholar
  159. 159.
    Nelis GF: The effect of oral cimetidine on the basal and stimulated values of prolactin, thyroid stimulating hormone, follicle stimulating hormone and luteinizing hormone.In H2-Antagonists. Torsoli A, Lucchelli PE, Brimblecombe RW, (eds). Amsterdam, Excerpta Medica, 1980, pp. 192–197Google Scholar
  160. 160.
    Corinaldesi R, Pasquali R, Paternico A, Stranghellini V, Paparo GF, Ricci-Maccarini M, Barbara L: Effects of short-and long-term administrations of famotidine and ranitidine on some pituitary, sexual and thyroid hormones. Drugs Exp Clin Res 13:647–654, 1987Google Scholar
  161. 161.
    Callaghan JT, Bergström RF, Rubin A, Chernish S, Crabtree R, Knadler MP, Obermever B, Offen WW, Schneck DW, Aronoff G, Lasseter KC: A pharmacokinetic profile of nizatidine in man. Scand J Gastroenterol 22(suppl 136):9–17, 1987Google Scholar
  162. 162.
    Jensen RT, Collen MJ, Pandol SJ, Allende HD, Raufman JP, Bissonnette BM, Duncan WC, Durgin PL, Gillin JC, Gardner JD: Cimetidine induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 308:881–887, 1983Google Scholar
  163. 163.
    Spence RW, Celestin LR: Gynaecomastia associated with cimetidine. Gut 20:154–157, 1979Google Scholar
  164. 164.
    Lindquist M, Edwards IR: Endocrine adverse effects of omeprazole. BMJ 305:451–452, 1992Google Scholar
  165. 165.
    Knigge U, Wollesen F, Dejgaard A, Thuesen B, Christiansen PM: Comparison between dose-responses of prolactin, thyroid stimulating hormone and growth hormone to two different histamine H2-receptor antagonists in normal men. Clin Endocrinol 15:585–592, 1981Google Scholar
  166. 166.
    Delle Fave GF, Tamburrano F, De Magistris L, et al: Variations in serum prolactin following cimetidine treatment for peptic ulcer disease. Rendic Gastroenterol 9:142–143, 1977Google Scholar
  167. 167.
    Majumdar SK, Thomson AD, Shaw GK: Cimetidine and serum prolactin BMJ 1:409, 1978Google Scholar
  168. 168.
    Burland WL, Gleadle RI, Lee RM, Rowley-Jones D, Groom GV: Prolactin responses to cimetidine. Br J Clin Pharmacol 7:19–21, 1979Google Scholar
  169. 169.
    Caldara R, Bierti L, Barbieri C, Cambielli M, Romussi M, Ferrari C: Stimulation of prolactin-release by intravenous cimetidine: A dose response study. J Endocrinol Invest 2:79–81, 1979Google Scholar
  170. 170.
    Carlson HE, Ippoliti AF: Cimetidine, a H2-antihistamine, stimulates prolactin secretion in man. J Clin Endocrinol Metab 45:367–370, 1977Google Scholar
  171. 171.
    Gonzalez-Villapando C, Szabo M, Frohman LA: Central nervous system mediated stimulation of prolactin secretion by cimetidine, a histamine H2-receptor antagonist: Impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. J Clin Endocrinol Metab 51:1417–1424, 1980Google Scholar
  172. 172.
    Hegarty JE, Summers K, Cone AM, Jenkins DR, Wood JR: Effect of 800 mg cimetidine and 300 mg ranitidine on serum prolactin. Gastroenterology 88:1415, 1985Google Scholar
  173. 173.
    Lombardo L: Hyperprolactinemia: Ranitidine revised adverse effect. Ital J Gastroenterol 17:160, 1985Google Scholar
  174. 174.
    Peden NR, Boyd EJS, Browning MCK, Saunders JAB, Wormsley KG: Effects of two histamine H2-receptor blockingdrugs on basal levels of gonadotrophins, prolactin, testosterone and oestradiol-17β during treatment of duodenal ulcer in male patients. Acta Endocrinol 96:564–568, 1981Google Scholar
  175. 175.
    Robins AH, McFayden ML: Effect of the new H2-receptor antagonist ranitidine on plasma prolactin levels in duodenal ulcer patients. J Pharm Pharmacol 33:615–616, 1981Google Scholar
  176. 176.
    Knigge U, Wollesen F, Dejgaard A, Larsen K, Christiansen PM: The effect of histamine stimulation and H2-receptor inhibition on the pituitary prolactin and ACTH release and on cortisol secretion in human males. Horm Metab Res 15:89–91, 1983Google Scholar
  177. 177.
    Pasquali R, Corinaldesi R, Patrono D, Capelli M, Stranghellini V, Melchionda N, Barbara L, Labo G: Effect of intravenous ranitidine on serum prolactin (PRL): Evidence for a sex difference. Gastroenterology 84:1271, 1983Google Scholar
  178. 178.
    Hayakawa A, Che K, Miyoshi A, Harawara S, Miwa T, Makabatake T: Properties of famotidine in relation to safety. Ital J Gastroenterol 16:174–176, 1984Google Scholar
  179. 179.
    Savarino V, Giusti M, Scalabrini P, Bessarione D, Magnolia MR, Granziera L, Celle G: Endocrine functions in man after long-term famotidine therapy. Dig Dis Sci 31:PS378, 1986Google Scholar
  180. 180.
    Franceschini R, Marabini A, Cataldi A, Salvemini M, Barrecca T, Rolandi E: Famotidine effects on prolactin, growth hormone, and thyrotropin pituitary secretion in man. Curr Ther Res 42:653–657, 1987Google Scholar
  181. 181.
    Usai P, Atzeni E, Zucca G, Loviselli A, Cherchi MV, Balzano S, Boy MF, Balestrieri A: Effects of the oral administration of famotidine on basal prolactin serum levels. Acta Toxicol Ther 7:57–64, 1986Google Scholar
  182. 182.
    Riley AJ, Maconochie J: Effect of histamine H2-receptor antagonists on vasopressin and aldosterone secretion. Acta Endocrinol 97(suppl 242):A316, 1981Google Scholar
  183. 183.
    Pomare EW, McFadyen ML: Hyperosmolar non-ketotic diabetes and cimetidine. Lancet 1:1202, 1978 (letter)Google Scholar
  184. 184.
    Londong W, Londong V, Cederberg C, Steffen H: Doseresponse study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 85:1373–1378, 1983Google Scholar
  185. 185.
    Müller P, Seitz HK, Simon B, et al: Vierwochige Omeprazolgabe: Einfluss auf Saureverhalten und basale Hormonspiegel. Z Gastroenterol 22:236–240, 1984Google Scholar
  186. 186.
    Howden CW, Kenyon CJ, Beastall GH, Reid JL: Inhibition by omeprazole of adrenocortical response to ACTH: Clinical studies and experiments on bovine adrenal cortexin vitro. Clin Sci 70:99–102, 1986Google Scholar
  187. 187.
    MacGilchrist AJ, Howden CW, Kenyon CJ, Beastall GH, Reid JL: The effects of omeprazole on endocrine function in man. Eur J Clin Pharmacol 32:423–425, 1987Google Scholar
  188. 188.
    Röhss K, Bergstrand R, Cederberg C, Heggelund A: Effect of intravenous omeprazole on basal and stimulated cortisol and 11-deoxycortisol levels in healthy subjects. Gastroenterology 98:A114, 1990Google Scholar
  189. 189.
    Allen JM, Adrian TE, Webster J, Howe A, Bloom SR: Effect of single dose of omeprazole on the gastrointestinal peptide response to food. Hepatogastroenterology 31:44–46, 1984Google Scholar
  190. 190.
    Zuchner H: Cholestatische Hepatose unter Cimetidine. Dtsch Med Wochenschr 102:1788–1789, 1977 (letter)Google Scholar
  191. 191.
    Villeneuve JP, Warner HA: Cimetidine hepatitis. Gastroenterology 77:143–144, 1979.Google Scholar
  192. 192.
    Lilly JR, Hitch DC, Javitt NB: Cimetidine cholestatic jaundice in children. J Surg Res 24:384–387, 1978Google Scholar
  193. 193.
    Lorenzini I, Jezequel AM, Orlandi F: Cimetidine-induced hepatitis. Electron microscopic observations and clinical pattern of liver injury Dig Dis Sci 26:275–280, 1981Google Scholar
  194. 194.
    Delpre G, Kadish U, Livni E: Hepatitis following cimetidine administration. Am J Med Sci 282:153–156, 1982Google Scholar
  195. 195.
    Adverse Drug Reaction Committee: Cimetidine. Med J Aust 1:394, 1980Google Scholar
  196. 196.
    Ruiz Del Arbol L, Moreira V, Moreno A, Hernández Ranz F, Cano A, García Plaza A: Bridging hepatic necrosis associated with cimetidine. Am J Gastroenterol 74:267–269, 1980Google Scholar
  197. 197.
    Van Steenbergen W, Vanstapel MJ, Desmet V, Van Kerckvoorde, L, De Keyzer R, Brijs R, Fevery J, De Groote J: Cimetidine-induced liver injury. Report of three cases. J Hepatol 1:359–368, 1985Google Scholar
  198. 198.
    Schwartz JT, Gyorkey F, Graham DY: Cimetidine hepatitis. J Clin Gastroenterol 8:681–686, 1986Google Scholar
  199. 199.
    Porter JB, Jick H, Perera DR, Ylvisaker JT, Hunter JR: Long-term follow-up study of cimetidine. Pharmacotherapy 83:68–75, 1984Google Scholar
  200. 200.
    Dobbs JH, Muir JG, Smith RN: H2-antagonists and hepatitis. Ann Intern Med 105:803, 1986 (letter)Google Scholar
  201. 201.
    Takeuchi M, Kaga M, Kiguchi M, Iwata M, Yamaguchi M, Shimpo K, Tanabe T: Chronic toxicity study of ranitidine hydrochloride orally administered in rat. J Toxicol Sci 8:(suppl 1):25–49, 1983Google Scholar
  202. 202.
    Barr GD, Piper DW: Possible ranitidine hepatitis. Med J Aust 2:241, 1981Google Scholar
  203. 203.
    Black M, Scott WE Jr, Kanter R: Possible ranitidine hepatoxicity. Ann Intern Med 101:208–210, 1984Google Scholar
  204. 204.
    Souza Lima MA: Hepatitis associated with ranitidine. Ann Intern Med 101:207–208, 1984Google Scholar
  205. 205.
    Zimmerman HJ, Jacob L, Bassan H, Gillespie J, Lukacs L, Abernathy CO: Effects of H2-blocking agents on hepatocytes in vitro: Correlation with potential for causing hepatic disease in patients. Proc Soc Exp Biol Med 182:511–514, 1986Google Scholar
  206. 206.
    Boyd PT, Lepre F, Dickey JD: Chronic active hepatitis associated with cimetidine. BMJ 298:324–325, 1989Google Scholar
  207. 207.
    Kanashima R, Nagasue N, Furusawa M, Inokuchi K: Inhibitory effect of cimetidine on liver regeneration after two-thirds hepatectomy in rats. Am J Surg 146:293–298, 1983Google Scholar
  208. 208.
    Kanashima R, Nagasue N, Sakato K: Ranitidine as an inhibitor of liver regeneration. Am J Surg 149:223–227, 1985Google Scholar
  209. 209.
    Lee S-D, Wang J-Y, Cho C-H, Wu J-C, Lu R-H, Lai K-H, Tsai Y-T, Lo K-J: Effects of H2-receptor antagonists on liver after partial hepatectomy or carbon tetrachloride induced hepatic injury. Scand J Gastroenterol 21:984–990, 1986Google Scholar
  210. 210.
    Nagasue N, Yukaya H, Ogawa Y, Sasaki Y, Hirose S: Prophylaxis of upper gastrointestinal bleeding with cimetidine in patients undergoing partial hepatectomy. Ann Chir Gynaecol 73:6–10, 1984Google Scholar
  211. 211.
    Feeley J, Wilkinson GR, Wood AJJ: Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304:692–695, 1981Google Scholar
  212. 212.
    Feely J, Guy E: Ranitidine also reduces liver blood flow. Lancet 2:169, 1982 (letter)Google Scholar
  213. 213.
    Ohnishi K, Saito M, Nomura F, Okuda K, Suzuki N, Ohtsuki T, Goto N, Takashi M: Effect of famotidine on hepatic hemodynamics and peptic ulcer. Am J Gastroenterol 82:415–418, 1987Google Scholar
  214. 214.
    Burroughs AK, Walt RP, Dunk AA: Effect of cimetidine on portal hypertension in cirrhotic patients. BMJ 284:1159–1160, 1982Google Scholar
  215. 215.
    Dunk AA, Jenkins WJ, Burroughs AK, Walt RP, Osuafor TOK, Sherlock S, Mackie S, Dick R: The effect of ranitidine on the plasma clearance and hepatic extraction of indocyanine green in patients with chronic liver disease. Br J Clin Pharmacol 16:117–120, 1983Google Scholar
  216. 216.
    Arditi M, Cravetto C, Molino G, Pera A, Ponti V: The effect of chronic treatment with gastric antisecretory drugs on functional liver plasma flow. Gastroenterology 84:1092, 1983Google Scholar
  217. 217.
    Ohnishi K, Kakayama T, Saito M, Hatano H, Nomura F, Iida S, Okuda K: Effects of cimetidine and ranitidine on splanchnic hemodynamics in patients with chronic liver disease. Am J Gastroenterol 80:290–293, 1985Google Scholar
  218. 218.
    Gustavsson S, Adami H-O, Lööf L, Nyberg A, Nyrén O: Rapid healing of duodenal ulcers with omeprazole: Doubleblind dose-comparative trial Lancet 2:124–125, 1983Google Scholar
  219. 219.
    Lööf L, Adami H-O, Gustavsson S, Nyberg A, Nyrén O, Lundborg P: Omeprazole: No evidence for frequent hepatic reactions. Lancet 1:1347–1348, 1984Google Scholar
  220. 220.
    Sölvell L: Safety aspects of omeprazole. Scand J Gastroenterol 21(suppl 118):129–133, 1986Google Scholar
  221. 221.
    Hui WM, Lam SK, Lau WY, Branicki FJ, Lok ASF, Ng MMT, Lai CL, Poon GP: Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse — a randomized double-blind study with weekly endoscopic assessment. J Gastroenterol Hepatol 4(suppl 2):35–43, 1989Google Scholar
  222. 222.
    Herting RL, Clay GA: Overview of clinical safety with misoprostol. Dig Dis Sci 30(suppl 11):185S-193S, 1985Google Scholar
  223. 223.
    Richter JM, Colditz GA, Huse DM, Delea TE, Oster G: Cimetidine and adverse reactions: A meta analysis of randomised clinical trials of short term therapy. Am J Med 87:278–284, 1989Google Scholar
  224. 224.
    Grant SM, Langtry HD, Brogden RN: Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37:801–870, 1989Google Scholar
  225. 225.
    Cloud ML: Safety of nizatidine in clinical trials conducted in the USA and Europe. Scand J Gastroenterol 22(suppl 136):29–36, 1987Google Scholar
  226. 226.
    Graham DY, Agrawal N, Roth SH: Prevention of NSAID-induced gastric ulcer with the synthetic prostaglandin, misoprostol — a multicentre, double-blind, placebo-controlled trial. Lancet 2:1277–1281, 1988Google Scholar
  227. 227.
    Meshkinpour H, Molinari MD, Gardner L, Berk JE, Hoehler FK: Cimetidine in the treatment of acute alcoholic pancreatitis. Gastroenterology 77:687–690, 1979Google Scholar
  228. 228.
    Hainaut P, Schapira M, Mugabo P, Cerulus G, Coche E: Cimetidine-induced acute pancreatitis. Rev Med Interne 8:516–518, 1987Google Scholar
  229. 229.
    Guo G, Levi R, Graver LM, Robertson DA, Gay WA: Inotropic effects of histamine in human myocardium: differentiation between positive and negative components. J Cardiovasc Pharmacol 6:1210–1215, 1984Google Scholar
  230. 230.
    Coruzzi G, Poli E, Fesani F, Medici D, Bertaccini G: Negative inotropic effect of some H2 receptor antagonists on the isolated human atria. Experientia 39:1284–1286, 1983Google Scholar
  231. 231.
    Smith CL, Bardgett DM, Hunter JM: Haemodynamic effects of cimetidine or ranitidine iv. Br J Anaesth 59:1397–1402, 1987Google Scholar
  232. 232.
    Jefferies DB, Vale JA: Cimetidine and bradycardia. Lancet 1:828, 1978Google Scholar
  233. 233.
    Zucchi M: Ranitidine-induced bradycardia. Lancet 2:160, 1982Google Scholar
  234. 234.
    Cohen J, Weetman AP, Dargie JH, Krikler DM: Life threatening arrhythmias and intravenous cimetidine. BMJ 2:768, 1979Google Scholar
  235. 235.
    Watson AJS, Watson R, Keogh JAB: Cimetidine induced arrhythmias. Ir J Med Sci 151:348, 1982Google Scholar
  236. 236.
    Baylack-Domengatroy E, Gallimard JF, Allal J, Rousseau G, Barraine R: Troubles de la conduction auriceoventriculaire sous ranitidine intra-veineuse. Ann Med Interne 138:140–141, 1987Google Scholar
  237. 237.
    Kirch W, Halabi H, Ohnhaus EE: Negative inotropic effects of famotidine. Lancet 2:684–685, 1987Google Scholar
  238. 238.
    Omote K, Namiki A, Nishikawa T, Hagiwar AT, Iwasaki H, Tsuchida H: Haemodynamic effects of famotidine and cimetidine in critically ill patients. Acta Anaesthesiol Scand 34:576–578, 1990.Google Scholar
  239. 239.
    Borow KM, Ehler D, Berlin RG, Neumann A: Influence of histamine receptors on basal left ventricular contractile tone in humans: Assessment using the H2-receptor antagonist famotidine and the beta adrenoceptor antagonist esmolol as pharmacologic probes. J Am Coll Cardiol 19:1229–1236, 1992Google Scholar
  240. 240.
    Picardo M, Santucci B: Urticaria from ranitidine. Contact Dermatitis 9:327–328, 1983Google Scholar
  241. 241.
    Parenti CM, Hoffman J: Hyperpyrexia associated with intravenous cimetidine therapy. Arch Intern Med 146:1821, 1986Google Scholar
  242. 242.
    Potter H, Byrne EB, Levobitz S: Fever after cimetidine and ranitidine. J Clin Gastroenterol 8:275, 1986Google Scholar
  243. 243.
    Watson AJS, Dalbow MH, Stachura I, et al.: Immunologic studies of cimetidine-induced nephropathy and polymyositis. N Engl J Med 308:142–145, 1983Google Scholar
  244. 244.
    Labeeuw M, Cabanne JE, Dubot P: Recurrent myalgias associated with cimetidine. Int J Clin Pharmacol Ther Toxicol 24:349, 1986Google Scholar
  245. 245.
    Allegri G, Pelligrini K, Dobrilla G: First-degree atrioventricular block in a young duodenal ulcer patient treated with a standard oral dose of ranitidine. Agents Actions 24:237, 1988Google Scholar
  246. 246.
    Atlay RD, Weekes AR: The treatment of gastrointestinal disease in pregnancy. Clin Obstet Gynaecol 13:335–347, 1986Google Scholar
  247. 247.
    Nelson MM, Forfar JO: Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. BMJ 1:523–527, 1971Google Scholar
  248. 248.
    Lewis JH, Weingold AAB: The Committee on FDA-Related Matters. GI drug column. The use of gastrointestinal drugs during pregnancy and lactation. Am J Gastroenterol 80:912–919, 1985Google Scholar
  249. 249.
    Berkowitz RL, Constan DR:In Handbook for Prescribing Medications during Pregnancy. Boston, Little, Brown & Co, 1981, pp 22–23Google Scholar
  250. 250.
    Anand S, Van Thiel DH: Prenatal and neonatal exposure to cimetidine results in gonadal and sexual dysfunction in adult males. Science 218:493–494, 1982Google Scholar
  251. 251.
    Brimblecombe RW, Duncan WAM, Durant GJ, Emmett JC, Ganellin CR, Leslie GB, Parsons ME: Characterization and development of cimetidine as a histamine H2 receptor antagonist. Gastroenterology 74:339–347, 1978Google Scholar
  252. 252.
    Parker S, Schade RR, Pohl CR, Gavaler JS, Van Thiel DH: Prenatal and neonatal exposure of male rat pups to cimetidine but not ranitidine adversely affects subsequent adult sexual functioning. Gastroenterology 86:675–680, 1984Google Scholar
  253. 253.
    Glade G, Saccar CL, Pereira GR: Cimetidine in pregnancy: Apparent transient liver impairment in the newborn. Am J Dis Child 134:87–88, 1980Google Scholar
  254. 254.
    Moir DD: Cimetidine, antacids, and pulmonary aspiration. Anesthesiology 59:81–83, 1983Google Scholar
  255. 255.
    McAuley DM, Moore J, Dundee JW, McCaughey W: Preliminary report on the use of ranitidine as an antacid in obstetrics. Ir J Med Sci 151:91–92, 1982Google Scholar
  256. 256.
    McNab MSP, Milne MK, Allison RH: Oral ranitidine in labour. Br J Anaesth 57:1040–1041, 1985Google Scholar
  257. 257.
    Colin Jones DG, Langman MJS, Lawson DH, Vessey MP: Cimetidine and gastric cancer; preliminary report from post marketing surveillance study. BMJ 285:1311–1313, 1982Google Scholar
  258. 258.
    Colin Jones DG, Langman MJS, Lawson DH, Vessey MP: Post marketing surveillance of the safety of cimetidine: 12 months mortality. BMJ 286:1713–1726, 1983Google Scholar
  259. 259.
    Colin Jones DG, Langman MJS, Lawson DH, Vessey MP: Post marketing surveillance of the safety of cimetidine: 12 months morbidity report. Q J Med 54:253–268, 1983Google Scholar
  260. 260.
    Colin Jones DG, Langman MJS, Lawson DH, Vessey MP: Post marketing surveillance of the safety of cimetidine: mortality during second, third and fourth years of follow up. BMJ 219:1084–1088, 1985Google Scholar
  261. 261.
    Colin Jones DG, Langman MJS, Lawson DH, Vessey MP: Review: Post marketing surveillance of the safety of cimetidine—the problems of data interpretation. Aliment Pharmacol Ther 1:167–177, 1987Google Scholar
  262. 262.
    Colin Jones DG, Langman MJS, Lawson DH, Logan FRA, Paterson KR, Vessey MP: Post marketing surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus. Q J Med 78:13–19, 1991Google Scholar
  263. 263.
    Langman MJS: Antisecretory drugs and gastric cancer. BMJ 290:1850–1852, 1985Google Scholar
  264. 264.
    Möller H, Lindvig K, Klefter R, Mosbech J, Möller Jensen O: Cancer occurrence in a cohort of patients treated with cimetidine. Gut 30:1558–1562, 1989Google Scholar
  265. 265.
    Ching MS, Mihaly GW, Morgan DJ, Date NM, Hardy KJ, Smallwood RA: Low clearance of cimetidine across the human placenta J Pharmacol Exp Ther 241:1006–1009, 1987Google Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • Richard A. Smallwood
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
  • Roger G. Berlin
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
  • Neal Castagnoli
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
  • Henk P. M. Festen
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
  • Christopher J. Hawkey
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
  • S. K. Lam
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
  • Michael J. S. Langman
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
  • Per Lundborg
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
  • Andrew Parkinson
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
  1. 1.Department of MedicineHeidelberg Repatriation HospitalMelbourneAustralia
  2. 2.Merck, Sharp and Dohme Research LaboratoriesWest PointUSA
  3. 3.Virginia Polytechnic Institute and State UniversityBlacksburgUSA
  4. 4.Department of MedicineUniversity of ConnecticutUSA
  5. 5.Department of MedicineUniversity Hospital, Queens Medical CentreNottinghamUK
  6. 6.Department of MedicineUniversity of Hong KongHong Kong
  7. 7.University Departmetn of TherapeuticsNottinghamUK
  8. 8.Astra Hässle ABMölndalSweden
  9. 9.Department of Pharmacology, Toxicology and TherapeuticsUniversity of Kansas Medical CenterKansas CityUSA
  10. 10.Department of MedicineRepatriation General HospitalHeidelbergAustralia

Personalised recommendations